MedTrace Logo

A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers

NCT00851383 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2012-04-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and immunogenicity of Ad35-GRIN/ENV HIV vaccine and Ad35-GRIN HIV vaccine administered intramuscularly at 0 and 6 months.

Conditions

  • HIV
  • HIV Infections

Interventions

BIOLOGICAL

Ad35-GRIN/ENV

This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.

BIOLOGICAL

Ad35-GRIN

This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.

Sponsors & Collaborators

  • University of Rochester

    collaborator OTHER

  • International AIDS Vaccine Initiative

    lead NETWORK

Principal Investigators

  • Michael Keefer · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00851383 on ClinicalTrials.gov